pharmaphorum April 19, 2024
Any company hoping to make headway in the market for obesity therapies will need deep pockets, so it’s an encouraging sign that start-up Metsera has launched with an impressive $290 million in financing.
Taking on established players like Novo Nordisk and Eli Lily will also need experienced leadership, and for that Metsera is drawing on the expertise of Clive Meanwell, former chief executive of The Medicines Company, who sold the company to Novartis for $9.7 billion.
Like Novo Nordisk and Lilly, Metsera has been set up to develop a pipeline of weight-loss therapies based on GLP-1 receptor agonism, with a focus on peptides and peptide-antibody conjugates.
Its lead product is an injectable GLP-1 therapy in early-stage clinical testing, which would...
Today's Sponsors
Today's Sponsor